Detalle Publicación

ARTÍCULO
Alemtuzumab in refractory Sezary syndrome
Autores: Alcantara Reifs, C. M. (Autor de correspondencia); Salido Vallejo, Rafael; Garnacho-Saucedo, G. M.; De la Corte-Sanchez, S.; González-Menchen, A.; Vélez García-Nieto, A.
Título de la revista: ANAIS BRASILEIROS DE DERMATOLOGIA
ISSN: 1806-4841
Volumen: 91
Número: 5
Páginas: 642 - 644
Fecha de publicación: 2016
Resumen:
Sezary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promising results in the treatment of this entity. We report the case of a 70-year-old male with refractory Sezary syndrome in whom treatment with alemtuzumab achieved an 80% skin lesion clearance with complete haematologic and radiologic response. The treatment was discontinued after 4 months due to adverse effects, with the patient showing a sustained response without disease progression after 13 months of follow-up.